Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib + Azacitidine in Higher Risk MDS
NCT02553941Phase 1Completed
- Start
- May 2016
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ibrutinib in myelodysplastic syndrome (MDS). Primary endpoint: Incidence of toxicity. Started May 2016; status: completed.
02
Drugs
ibrutinib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02553941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02553941.